Hypoxia in the intestine or solid tumors: A beneficial or deleterious alarm signal?

European Journal of Immunology

Volumn 44, Issue 9, 2014, Pages 2550-2557

  Shehade, Hussein ^a   Oldenhove, Guillaume ^a   Moser, Muriel ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

Hypoxia inducible factors; Immunity; Macrophages; T helper subsets; Vasculature

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; OXYGEN; TUMOR PROTEIN;

ANIMAL; ANOXIA; CELL PROLIFERATION; CELL SURVIVAL; HUMAN; HYPOXIA INDUCIBLE FACTORS; IMMUNITY; INFLAMMATION; INTESTINE; MACROPHAGE; METABOLISM; NEOPLASM; PATHOLOGY; REVIEW; T HELPER SUBSETS; TUMOR MICROENVIRONMENT; VASCULARIZATION;

HYPOXIA INDUCIBLE FACTORS; IMMUNITY; MACROPHAGES; T HELPER SUBSETS; VASCULATURE;

ANIMALS; ANOXIA; CELL PROLIFERATION; CELL SURVIVAL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INFLAMMATION; INTESTINES; NEOPLASM PROTEINS; NEOPLASMS; OXYGEN; TUMOR MICROENVIRONMENT;

EID: 84907853348     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201444719     Document Type: Review

References (64)

1. Semenza, G. L., Life with oxygen. Science 2007. 318: 62-64.
2. Semenza, G., Hypoxia-inducible factors in physiology and medicine. Cell 2012. 148: 399-408.
3. Leach, R. M. and Treacher, D. F., Oxygen transport-2. Tissue hypoxia. BMJ 1998. 317: 1370-1373.
4. Jiang, B. H., Semenza, G. L., Bauer, C. andMarti, H. H., Hypoxia-inducible factor 1 levels vary exponentially over a physiologically relevant range of O2 tension. Am. J. Physiol. 1996. 271: C1172-C1180.
5. Lando, D., Peet, D. J.,Whelan, D. a., Gorman, J. J. and Whitelaw, M. L., Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 2002. 295: 858-861.
6. Mastrogiannaki, M., Matak, P., Keith, B., Simon, M. C., Vaulont, S. and Peyssonnaux, C., HIF-2 α, but not HIF-1 α, promotes iron absorption in mice. 2009. 119: 1159-1166.
7. Patel, S. a. and Simon, M. C., Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ. 2008. 15: 628-634.
8. Makino, Y., Cao, R., Svensson, K., Bertilsson, G., Asman, M., Tanaka, H., Cao, Y. et al., Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 2001. 414: 550-554.
9. Zhang, P., Yao, Q., Lu, L., Li, Y., Chen, P.-J. and Duan, C., Hypoxiainducible factor 3 is an oxygen-dependent transcription activator and regulates a distinct transcriptional response to hypoxia. Cell Rep. 2014. 6: 1110-1121.
10. Wang, G. L. and Semenza, G. L., Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 1993. 82: 3610-3615.
11. Maxwell, P. H., Pugh, C.W. and Ratcliffe, P. J., Inducible operation of the erythropoietin 3' enhancer in multiple cell lines: evidence for a widespread oxygen-sensing mechanism. Proc. Natl. Acad. Sci. USA 1993. 90: 2423-2427.
12. Selak, M. a., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y. et al., Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell 2005. 7: 77-85.
13. Isaacs, J. S., Jung, Y. J., Mole, D. R., Lee, S., Torres-Cabala, C., Chung, Y.-L., Merino, M. et al., HIF overexpression correlates with biallelic' regulation of HIF stability. Cancer Cell 2005. 8: 143-153.
14. Rius, J., Guma, M., Schachtrup, C., Akassoglou, K., Zinkernagel, A. S., Nizet, V., Johnson, R. S. et al., NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature 2008. 453: 807-811.
15. Nakamura, H., Makino, Y., Okamoto, K., Poellinger, L., Ohnuma, K., Morimoto, C. and Tanaka, H., TCR engagement increases hypoxiainducible factor-1 protein synthesis via rapamycin-sensitive pathway under hypoxic conditions in human peripheral T cells. J. Immunol. 2005. 174: 7592-7599.
16. Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T. et al., A human gut microbial gene catalogue established by metagenomic sequencing. Nature 2010. 464: 59-65.
17. Kurashima, Y., Goto, Y. and Kiyono, H., Mucosal innate immune cells regulate both gut homeostasis and intestinal inflammation. Eur. J. Immunol. 2013. 43: 3108-3115.
18. Maloy, K. J. and Powrie, F., Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011. 474: 298-306.
19. Colgan, S. P. and Taylor, C. T., Hypoxia: an alarm signal during intestinal inflammation. Nat. Rev. Gastroenterol. Hepatol. 2010. 7: 281-287.
20. Karhausen, J., Furuta, G. T., Tomaszewski, J. E., Johnson, R. S., Colgan, S. P. and Haase, V. H., Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J. Clin. Invest. 2004. 114: 1098-1106.
21. Campbell, E. L., Bruyninckx, W. J., Kelly, C. J., Glover, L. E., McNamee, E. N., Bowers, B. E., Bayless, A. J. et al., Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation. Immunity 2014. 40: 66-77.
22. Panwala, C. M., Jones, J. C. and Viney, J. L., A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J. Immunol. 1998. 161: 5733-5744.
23. Mashimo, H., Wu, D. C., Podolsky, D. K. and Fishman, M. C., Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996. 274: 262-265.
24. Furuta G. T., Turner, J. R., Taylor, C. T., Hershberg, R. M., Comerford, K., Narravula, S., Podolsky, D. K. et al., Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J. Exp. Med. 2001; 193: 1027-1034.
25. Synnestvedt, K., Ecto-5'-nucleotidase (CD73) regulation by hypoxiainducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 2002. 110: 993-1002.
26. Harris, N. R., Carter, P. R., Yadav, A. S., Watts, M. N., Zhang, S., Kosloski-Davidson, M. and Grisham, M. B., Relationship between inflammation and tissue hypoxia in a mouse model of chronic colitis. Inflamm. Bowel Dis. 2010. 17: 1-5. DOI: 10.1002/ibd.21423.
27. Hultén, L., Lindhagen, J., Lundgren, O., Fasth, S. and Ahrén, C., Regional intestinal blood flow in ulcerative colitis and Crohn's disease. Gastroenterology 1977. 72: 388-396.
28. Higashiyama, M., Hokari, R., Hozumi, H., Kurihara, C., Ueda, T., Watanabe, C., Tomita, K. et al., HIF-1 in T cells ameliorated dextran sodium sulfate-induced murine colitis. J. Leukoc. Biol. 2012. 91: 901-909.
29. Clambey, E. T., McNamee, E. N., Westrich, J. A., Glover, L. E., Campbell, E. L., Jedlicka, P., de Zoeten, E. F. et al., Hypoxia-inducible factor-1 alphadependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc. Natl. Acad. Sci. USA 2012. 109: E2784-E2793.
30. Glover, L. E., Irizarry, K., Scully, M., Campbell, E. L., Bowers, B. E., Aherne, C. M., Kominsky, D. J. et al., IFN-γ attenuates hypoxia-inducible factor (HIF) activity in intestinal epithelial cells through transcriptional repression of HIF-1ß. J. Immunol. 2011. 186: 1790-1798.
31. Buckanovich, R. J., Facciabene, A., Kim, S., Benencia, F., Sasaroli, D., Balint, K., Katsaros, D. et al., Endothelin B receptormediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 2008. 14: 28-36.
32. Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X. et al., A2A adenosine receptor protects tumors from antitumor T cells. Proc. Natl. Acad. Sci. USA 2006. 103: 13132- 13137.
33. Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P.,Gimotty, P. A.et al., Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011. 475: 226-230.
34. Kudo-Saito, C., Shirako, H., Ohike, M., Tsukamoto, N. and Kawakami, Y., CCL2 is critical for immunosuppression to promote cancer metastasis. Clin. Exp. Metastasis 2013. 30: 393-405.
35. Barsoum, I. B., Smallwood, C. A., Siemens, D. R. and Graham, C. H., A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells. Cancer Res. 2014. 74: 665-674.
36. Cao, Y., Eble, J. M., Moon, E., Yuan, H., Weitzel, D. H., Landon, C. D., Nien, C. Y.-C. et al., Tumor cells upregulate normoxic HIF-1a in response to doxorubicin. Cancer Res. 2013. 73: 6230-6242.
37. Pawlus, M. R., Wang, L. and Hu, C.-J., STAT3 and HIF1a cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells. Oncogene 2013. 33: 1-10.
38. Rice, C. and Huang, L. E., From antiangiogenesis to hypoxia: current research and future directions. Cancer Manag. Res. 2010. 3: 9-16.
39. Bellone, M. and Calcinotto, A., Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front. Oncol. 2013. 3: 231.
40. Sun, J., Wang, D.-A., Jain, R. K., Carie, A., Paquette, S., Ennis, E., Blaskovich, M. A. et al., Inhibiting angiogenesis and tumorigenesis by a synthetic molecule that blocks binding of both VEGF and PDGF to their receptors. Oncogene 2005. 24: 4701-4709.
41. Biswas, S. K. and Mantovani, A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 2010. 11: 889-896.
42. Biswas, S. K., Allavena, P. and Mantovani, A., Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin. Immunopathol. 2013. 35: 585-600.
43. Mitchem, J. B., Brennan, D. J., Knolhoff, B. L., Belt, B. A., Zhu, Y., Sanford, D. E., Belaygorod, L. et al., Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013. 73: 1128-1141.
44. Medrek, C., Pontén, F., Jirström, K. and Leandersson, K., The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer 2012. 12: 306.
45. Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L. et al., HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011. 19: 31-44.
46. Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M. et al., Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumormicroenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. USA 2012. 109: 17561- 17566.
47. Casazza, A., Laoui, D., Wenes, M., Rizzolio, S., Bassani, N., Mambretti, M., Deschoemaeker, S. et al., Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell. 2013. 24: 695-709.
48. Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V. et al., PD-L1 is a novel direct target of HIF-1 , and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 2014. 211: 781-790.
49. Doedens, A. L., Phan, A. T., Stradner, M. H., Fujimoto, J. K., Nguyen, J. V., Yang, E., Johnson, R. S. et al., Hypoxia-inducible factors enhance the effector responses of CD8(+) T cells to persistent antigen. Nat. Immunol. 2013. 14: 1-11.
50. Mamlouk, S., Kalucka, J., Singh, R. P., Franke, K., Muschter, A., Langer, A., Jakob, C. et al., Loss of prolyl hydroxylase-2 in myeloid cells and T-lymphocytes impairs tumor development. Int. J. Cancer 2014. 134: 849- 858.
51. Thiel, M., Caldwell, C. C., Kreth, S., Kuboki, S., Chen, P., Smith, P., Ohta, A. et al., Targeted deletion of HIF-1alpha gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septicmice survival. PLoS One 2007. 2: e853.
52. Kojima, H., Gu, H., Nomura, S., Caldwell, C. C., Kobata, T., Carmeliet, P., Semenza, G. L. et al., Abnormal B lymphocyte development and autoimmunity in hypoxia-inducible factor 1alpha-deficient chimeric mice. Proc. Natl. Acad. Sci. USA 2002. 99: 2170-2174.
53. Georgiev, P., Belikoff, B. G., Hatfield, S., Ohta, A., Sitkovsky, M. V. and Lukashev, D., Genetic deletion of the HIF-1a isoform I.1 in T cells enhances antibacterial immunity and improves survival in a murine peritonitis model. Eur. J. Immunol. 2013. 43: 655-666.
54. Shi, L. Z., Wang, R., Huang, G., Vogel, P., Neale, G., Green, D. R. and Chi, H., HIF1{alpha}-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J. Exp. Med. 2011. 208: 1367-1376.
55. Dang, E. V., Barbi, J., Yang, H., Jinasena, D., Yu, H., Zheng, Y., Bordman, Z. et al., Control of T H 17/T reg balance by hypoxia-inducible factor 1. Cell 2011. 146: 1-13.
56. Hu, F., Mu, R., Zhu, J., Shi, L., Li, Y., Liu, X., Shao, W. et al., Hypoxia and hypoxia-inducible factor-1a provoke toll-like receptor signalling-induced inflammation in rheumatoid arthritis. Ann. Rheum. Dis. 2013. 73: 928-936.
57. Laresgoiti-Servitje, E.,Aleading role for the immune system in the pathophysiology of preeclampsia. J. Leukoc. Biol. 2013. 94: 247-257.
58. McNamee, E. N., Korns Johnson, D., Homann, D. and Clambey, E. T., Hypoxia and hypoxia-inducible factors as regulators of T cell development, differentiation, and function. Immunol. Res. 2013. 55: 58-70.
59. Cummins, E. P., Seeballuck, F., Keely, S. J., Mangan, N. E., Callanan, J. J., Fallon, P. G. and Taylor, C. T., The hydroxylase inhibitor dimethyloxalylglycine is protective in a murine model of colitis. Gastroenterology 2008. 134: 156-165.
60. Robinson, A., Keely, S., Karhausen, J., Gerich, M. E., Furuta, G. T. and Colgan, S. P., Mucosal protection by hypoxia-inducible factor prolyl hydroxylase inhibition. Gastroenterology 2008. 134: 145-155.
61. Xue, X., Ramakrishnan, S. K. and Shah, Y. M., Activation of HIF-1a does not increase intestinal tumorigenesis. Am. J. Physiol. Gastrointest. Liver Physiol. 2014. 307: G187-G195.
62. Lee, K., Zhang, H. and Qian, D., Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl. Acad. Sci. USA 2009. 106: 17910-17915.
63. Yoshida, T., Zhang, H., Iwase, T., Shen, J., Semenza, G. L. and Campochiaro, P. A., Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization. FASEB J. 2010. 24: 1759-1767.
64. Griffioen, A. W. and Vyth-Dreese, F. A., Angiostasis as a way to improve immunotherapy. Thromb. Haemost. 2009. 101: 1025-1031.